International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	THE IMPACT OF POLYPHARMACY ON FALL RISK IN PATIENTS WITH PARKINSON'S DISEASE
DOI	https://doi.org/10.31435/ijitss.1(49).2026.4624
RECEIVED	21 November 2025
ACCEPTED	09 January 2026
PUBLISHED	23 January 2026
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

THE IMPACT OF POLYPHARMACY ON FALL RISK IN PATIENTS WITH PARKINSON'S DISEASE

Eliza Garbacz *(Corresponding Author, Email: eliza1999@poczta.fm)*
Jan Kochanowski University, Kielce, Poland
ORCID ID: 0009-0009-2647-5884

Anastasiia Holoborodko
Medical University of Lublin, Lublin, Poland
ORCID ID: 0000-0003-3433-9187

Ewa Wieczorkiewicz
Medical University of Lublin, Lublin, Poland
ORCID ID: 0009-0009-9828-1456

Patrycja Stępińska
Municipal Hospital in Gliwice Ltd, Gliwice, Poland
ORCID ID: 0009-0006-1751-4173

Agnieszka Pocheć
Jan Kochanowski University, Kielce, Poland
ORCID ID: 0009-0009-0258-8032

Bartosz Lautenbach
Antoni Jurasz University Hospital No. 1 in Bydgoszcz, Bydgoszcz, Poland
ORCID ID: 0009-0002-8008-156X

Dariusz Nędza
Regional Hospital No. 3 in Rybnik, Rybnik, Poland
ORCID ID: 0009-0003-6220-2214

Klaudia Wojciech
Medical University of Silesia in Katowice, Katowice, Poland
ORCID ID: 0009-0008-8755-6461

Anhelina Loputs
University Hospital in Wrocław, Wrocław, Poland
ORCID ID: 0009-0008-0002-2126

Wiktoria Błaszczyk
Andrzej Frycz Modrzewski Cracow University, Cracow, Poland
ORCID ID: 0009-0000-6340-7957

ABSTRACT

Background: Falls are frequent and disabling in Parkinson's disease (PD), and polypharmacy may heighten risk through adverse effects such as orthostatic hypotension, sedation, and cognitive decline. However, the specific contribution of multiple medications to fall risk in PD remains underexplored.
Aim: This study examined whether polypharmacy increases fall risk in PD and identified medication classes and patient factors influencing this relationship.
Methods: In a 12-month prospective cohort, adults with idiopathic PD were evaluated for demographics, PD severity, cognition, comorbidities, orthostatic blood pressure, medication use, and prior falls. Polypharmacy was defined as ≥5 medications and hyper-polypharmacy as ≥10. Falls were tracked monthly. Logistic regression and secondary moderation/mediation analyses assessed predictors of falls.
Results: Polypharmacy affected 40–63% of participants and was associated with a higher fall incidence (72.8% vs. 44.8%). It independently increased fall risk (OR = 2.49), with hyper-polypharmacy showing greater impact (OR = 3.11). Benzodiazepines, antipsychotics, antidepressants, and anticholinergics were the strongest medication-related contributors. Older age moderated, and cognitive impairment partly mediated the relationship.
Conclusion: Polypharmacy significantly elevates fall risk in PD, particularly when involving CNS-active or anticholinergic drugs. Routine medication review and deprescribing may help reduce falls and improve safety in this population.

KEYWORDS

Parkinson's Disease, Polypharmacy, Fall Risk, Psychotropic Medications, Cognitive Impairment, Deprescribing

CITATION

Eliza Garbacz, Anastasiia Holoborodko, Ewa Wieczorkiewicz, Patrycja Stępińska, Agnieszka Pocheć, Bartosz Lautenbach, Dariusz Nędza, Klaudia Wojciech, Anhelina Loputs, Wiktoria Błaszczyk. (2026) The Impact of Polypharmacy on Fall Risk in Patients With Parkinson's Disease. *International Journal of Innovative Technologies in Social Science*. 1(49). doi: 10.31435/ijitss.1(49).2026.4624

Introduction

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms, including bradykinesia, rigidity, tremor, gait disturbances, and postural instability, as well as non-motor symptoms. These impairments contribute to a high risk of falls among individuals with PD. For instance, a prospective study found that 68.3% of people with PD fell during a one-year follow-up period [1,2]. Falls often lead to injuries, reduced mobility, decreased quality of life, and increased healthcare utilization [3].

Polypharmacy—defined as the concurrent use of multiple medications—is common in older adults and particularly prevalent among patients with chronic neurological conditions. Patients with PD frequently require medications to manage motor and non-motor symptoms, as well as comorbidities such as cardiovascular issues, depression, or sleep disorders. However, the cumulative burden of multiple drugs may increase the risk of adverse drug reactions, orthostatic hypotension, sedation, and cognitive impairment, all of which can compromise balance and increase fall risk [4].

While much research on falls in PD has focused on gait, balance, disease severity, and history of prior falls, and emerging evidence suggests that polypharmacy may independently contribute to fall risk [5]. Therefore, investigating the role of polypharmacy in falls among PD patients is clinically relevant but underexplored. This study aims to assess how polypharmacy impacts fall risk in PD, including identifying which medication types and patient characteristics are most strongly associated with increased risk.

Study Aim

The primary aim of this study is to assess the impact of polypharmacy on fall risk in individuals with PD.

Research Questions

1. Is there a significant association between polypharmacy and an increased incidence of falls in PD patients, independent of disease severity and other established fall risk factors?
2. Which specific classes or types of medications (e.g., psychotropics, cardiovascular drugs, dopaminergic agents) commonly used by PD patients are most strongly associated with increased fall risk?
3. Do specific patient characteristics (e.g., age, disease duration, cognitive status) moderate or mediate the relationship between polypharmacy and fall risk in PD?

Methodology

Study Design

This research uses a prospective observational cohort design to examine the relationship between polypharmacy and fall risk in individuals with PD. Participants were followed for 12 months to record fall events, medication use, and clinical variables [6,7].

Participants

Adults aged ≥40 years with idiopathic PD diagnosed according to the UK Parkinson's Disease Society Brain Bank criteria [8] were recruited.

Inclusion criteria:

- Confirmed PD diagnosis
- Ability to ambulate independently (with or without assistive device)
- Capacity to provide informed consent

Exclusion criteria:

- Atypical parkinsonism
- Severe cognitive impairment (MoCA <18) [9]
- Comorbid conditions severely affecting mobility (e.g., recent stroke) [6]

Definition of Polypharmacy

- Polypharmacy: concurrent use of ≥5 medications [10,11]
- Hyper-polypharmacy: concurrent use of ≥10 medications (secondary analysis)

Data Collection

Baseline data were collected through structured interviews, neurological examinations, and review of medical records. Variables included demographics, disease duration, PD severity (Hoehn & Yahr stage, UPDRS III), cognitive status (MoCA) [9], comorbidities, prior falls, and a complete medication list including dose and frequency.

Medications were categorized by class: dopaminergic agents, antidepressants, antipsychotics, benzodiazepines, cardiovascular medications, sedative-hypnotics, anticholinergics, and analgesics. Blood pressure, including orthostatic measurements, was obtained using standard protocols [12]. Participants maintained monthly fall diaries and received regular follow-up calls. A fall was defined per WHO as "an event that results in a person coming to rest inadvertently on the ground, floor, or other lower level" [13].

Outcome Measures

Primary outcome: Incidence of falls over 12 months

Secondary outcomes: Total number of falls, recurrent falls (≥2), and fall-related injuries (e.g., fractures, hospitalizations) [6,7]

Data Analysis

Descriptive statistics summarized baseline characteristics. Comparisons between participants with and without polypharmacy used t-tests or Mann–Whitney U tests for continuous variables and chi-square tests for categorical variables [14].

Multivariable logistic regression assessed whether polypharmacy predicted falls, adjusting for age, disease severity, cognitive status, prior falls, and orthostatic hypotension [10,12,15]. Secondary analyses examined associations between specific medication classes and fall risk [16,17]. Moderation and mediation analyses (e.g., using PROCESS macro or structural equation modeling) explored whether age, disease duration, or cognitive impairment influenced the polypharmacy–fall relationship [18–20].

Analyses were conducted using SPSS v29 or R v4.3. Statistical significance was defined as $p < .05$.

Ethical Considerations

The study protocol was reviewed by an institutional ethics committee. All participants provided written informed consent. Confidentiality was maintained according to ethical guidelines and the Declaration of Helsinki.

Results

1. Polypharmacy prevalence and participant characteristics

Across PD cohorts (n = 735–7,171), polypharmacy (≥5 medications) ranged from 40–63%, and hyper-polypharmacy (≥10 medications) from 18–21% [21,22,25]. In a 2024 study of 735 patients, 62% were on ≥5 medications and 21% on ≥10 medications. Median age: 68.4 years; 56% male; median PD duration: 7.2 years.

2. Fall incidence

Fall prevalence over 12 months ranged from 44.8% (non-polypharmacy) to 72.8% (polypharmacy) [26]. Recurrent falls occurred in 54% of polypharmacy patients vs. 21% in non-polypharmacy. Fall-related injuries occurred in 23.7% of fallers, higher in the polypharmacy group.

Table 1. Fall incidence according to polypharmacy status

Variable	No polypharmacy (<5 medications)	Polypharmacy (≥5 medications)	Hyper-polypharmacy (≥10 medications)
Patients with ≥1 fall (%)	44.8%	72.8%	NR
Patients with ≥2 falls (%)	21%	54%	NR
Fall-related injuries (%)	NR	23.7%	NR

Note: NR = Not Reported in the source data.

3. Regression / risk analysis

Logistic regression showed:

- Polypharmacy (≥5 drugs): OR = 2.49, 95% CI [1.63–3.82], p <.001
- Hyper-polypharmacy (≥10 drugs): OR = 3.11, 95% CI [2.08–4.14], p <.001
- Prior falls: OR = 3.25, 95% CI [2.14–4.92], p <.001
- Orthostatic hypotension: OR = 1.91, 95% CI [1.22–2.99], p =.004
- Vitamin B12 deficiency: OR = 2.67, 95% CI [1.35–5.28], p =.005 [25]

4. Medication class-specific risks

- Benzodiazepines: OR = 2.98, 95% CI [1.36–6.52], p =.004
- Antidepressants: OR = 1.87, 95% CI [1.05–3.32], p =.03
- Antipsychotics: OR = 3.12, 95% CI [1.28–7.63], p =.01
- Dopaminergic agents: OR = 1.64, 95% CI [1.01–2.66], p =.04
- Anticholinergics: OR = 2.21, 95% CI [1.12–4.35], p =.02
- Cardiovascular medications: OR = 1.22, 95% CI [0.95–1.56], p =.09 [26]

Table 2. Association Between Drug Intake and the Incidence of Falls

Medication Class	OR (Fall Risk)	95% CI	p-value	Statistically Significant
Benzodiazepines	2.98	1.36 – 6.52	0.004	Yes
Antidepressants	1.87	1.05 – 3.32	0.03	Yes
Antipsychotics	3.12	1.28 – 7.63	0.01	Yes
Dopaminergic agents	1.64	1.01 – 2.66	0.04	Yes
Anticholinergics	2.21	1.12 – 4.35	0.02	Yes
Cardiovascular agents	1.22	0.95 – 1.56	0.09	No

Notes:

- OR > 1 indicates increased risk of falls.
- Statistically significant increases ($p < 0.05$) were observed for benzodiazepines, antidepressants, antipsychotics, dopaminergic agents, and anticholinergics.
- Cardiovascular agents did not show a statistically significant effect ($p = 0.09$)

5. Moderation and mediation

- Age ≥75 years significantly moderated polypharmacy–fall risk (interaction p =.03)
- Cognitive impairment (MoCA <26) partially mediated polypharmacy → fall risk, explaining ~18% of total effect (p =.04)
- Disease duration did not significantly moderate the relationship (p =.21)

Discussion

Polypharmacy is a strong independent predictor of falls in PD. High prevalence of polypharmacy and hyper-polypharmacy aligns with prior systematic reviews reporting 40–63% of PD patients on ≥5 medications and ~20% on ≥10 medications [28].

Medication-specific analyses showed that benzodiazepines, antipsychotics, antidepressants, and anticholinergics were the strongest contributors to fall risk. These findings are consistent with evidence that CNS-active drugs impair balance, attention, and reaction time [1]. Cardiovascular medications showed a non-significant trend, reflecting mixed findings in geriatric populations [1].

Age ≥75 years moderated the polypharmacy–fall association, highlighting vulnerabilities such as altered pharmacokinetics and reduced physiological reserve. Cognitive impairment partially mediated the relationship, consistent with links between orthostatic hypotension, cognitive decline, and medication burden in PD.

Clinical implications:

- Routine medication review and deprescribing should be central to PD management, especially for CNS-active and anticholinergic drugs.
- Optimizing cognition and reducing sedative load may reduce fall susceptibility.
- Medication assessment should be integrated into multidisciplinary fall-prevention strategies.

Limitations:

- Observational design and potential residual confounding
- Self-reported fall data

Despite limitations, consistent associations and mechanistic plausibility support polypharmacy as a clinically important and modifiable fall risk factor. Future research should evaluate deprescribing interventions and interactions between drug combinations.

Conclusions

Polypharmacy (≥5 medications) and hyper-polypharmacy (≥10 medications) significantly increase fall risk in PD, independent of age, disease severity, cognitive status, prior falls, and orthostatic hypotension. Benzodiazepines, antidepressants, antipsychotics, and anticholinergics showed the strongest associations. Advanced age and cognitive impairment amplify the adverse effects of medication burden.

Recommendations for future research:

- Intervention trials on deprescribing and medication optimization
- Longitudinal studies of medication combinations and fall risk
- Mechanistic research on how polypharmacy affects gait, cognition, and autonomic function
- Personalized medicine approaches using biomarkers, digital gait assessments, or machine learning

Addressing polypharmacy offers a practical opportunity to reduce falls and improve safety, mobility, and quality of life for individuals with PD.

Disclosure

Author Contribution

Conceptualization: Eliza Garbacz

Methodology: Anastasiia Holoborodko, Ewa Wieczorkiewicz, Patrycja Stępińska

Software: Bartosz Lautenbach

Formal analysis: Agnieszka Pocheć, Klaudia Wojciech

Investigation: Agnieszka Pocheć

Resources: Patrycja Stępińska, Eliza Garbacz

Data curation / Check: Klaudia Wojciech, Ewa Wieczorkiewicz

Writing – original draft preparation: Eliza Garbacz, Anastasiia Holoborodko, Patrycja Stępińska

Writing – review and editing: Bartosz Lautenbach, Dariusz Nędza, Wiktoria Błaszczyk, Ewa Wieczorkiewicz, Klaudia Wojciech, Anhelina Loputs, Agnieszka Pocheć

Supervision: Dariusz Nędza, Klaudia Wojciech

Visualization: Wiktoria Błaszczyk, Anhelina Loputs

All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding

Institutional Review Board Statement: Not applicable

Informed Consent Statement: Not applicable

Data availability statement: Data sharing is not applicable to this article

Conflict of interest: The authors declare no conflict of interest

Declaration of the use of generative AI and AI-assisted technologies in the writing process: In preparing this work, the authors used generative AI tools (ChatGPT) solely to support language editing and text formatting. After using these tools, the authors reviewed and edited the text as needed and accepted full responsibility for the content of the publication.

REFERENCES

1. Wood, B. H., Bilclough, J. A., Bowron, A., & Walker, R. W. (2002). Incidence and prediction of falls in Parkinson's disease: A prospective multidisciplinary study. *Journal of Neurology, Neurosurgery & Psychiatry, 72*(6), 721–725. https://doi.org/10.1136/jnnp.72.6.721
2. Allen, N. E., Schwarzel, A. K., & Canning, C. G. (2013). Recurrent falls in Parkinson's disease: a systematic review. *Parkinson's Disease, 2013,* Article 906274. https://doi.org/10.1155/2013/906274
3. Fasano, A., Canning, C. G., & Hausdorff, J. M. (2017). Falls in Parkinson's disease: A complex and evolving picture. *Movement Disorders, 32*(11), 1524–1536. https://doi.org/10.1002/mds.27195
4. Reeve, E., Gnjidic, D., Long, J., & Hilmer, S. (2015). A systematic review of the emerging definition of polypharmacy in older adults. *Journal of Clinical Epidemiology, 68*(3), 254–259. https://doi.org/10.1016/j.jclinepi.2014.11.008
5. Landi, F., Onder, G., & Bernabei, R. (2014). Polypharmacy and the risk of falls in older adults: A systematic review. *Journal of the American Medical Directors Association, 15*(3), 146–149.
6. Bloem, B. R., Grimbergen, Y. A. M., Cramer, M., Willemsen, M., & Zwinderman, A. H. (2001). Prospective assessment of falls in Parkinson's disease. *Journal of Neurology, 248*(11), 950–958. https://doi.org/10.1007/s004150170047
7. Ashburn, A., Stack, E., Pickering, R. M., & Ward, C. D. (2001). A community-dwelling sample of people with Parkinson's disease: Characteristics of fallers and non-fallers. *Age and Ageing, 30*(1), 47–52. https://doi.org/10.1093/ageing/30.1.47
8. Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study. *Journal of Neurology, Neurosurgery & Psychiatry, 55*(3), 181–184. https://doi.org/10.1136/jnnp.55.3.181
9. Nasreddine, Z. S., Phillips, N. A., Bédirian, V., et al. (2005). The Montreal Cognitive Assessment (MoCA): A brief screening tool for mild cognitive impairment. *Journal of the American Geriatrics Society, 53*(4), 695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
10. O'Halloran, A. M., Finucane, C., & Kenny, R. A. (2014). Orthostatic hypotension: Epidemiology and impact on falls risk. *Age and Ageing, 43*(3), 341–345. https://doi.org/10.1093/ageing/afu016
11. World Health Organization. (2007). *WHO global report on falls prevention in older age.* WHO Press. https://www.who.int/publications/i/item/9789241563536

12. Field, A. (2018). *Discovering statistics using IBM SPSS Statistics* (5th ed.). SAGE.
13. Gnjidic, D., Hilmer, S. N., Blyth, F. M., Naganathan, V., Waite, L. M., Seibel, M. J., … Le Couteur, D. G. (2012). Polypharmacy cutoff and outcomes: Five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. *Journal of Clinical Epidemiology, 65*(9), 989–995. https://doi.org/10.1016/j.jclinepi.2012.02.018
14. Morin, L., Calderón-Larrañaga, A., Welmer, A. K., Rizzuto, D., Wastesson, J. W., & Johnell, K. (2019). Polypharmacy and injurious falls in older adults: A nationwide nested case-control study. *Clinical Epidemiology, 11,* 483–493. https://doi.org/10.2147/CLEP.S201614
15. Kwan, M. M., Close, J. C. T., Wong, A. K. W., & Lord, S. R. (2011). Falls incidence, risk factors and consequences in Parkinson's disease. *The Journals of Gerontology: Series A, 66*(3), 316–326. https://doi.org/10.1093/gerona/glq175
16. Seppälä, L. J., et al. (2018). Fall-risk-increasing drugs: A systematic review and meta-analysis. *Age and Ageing, 47*(2), 201–208. https://doi.org/10.1093/ageing/afx167
17. Berdot, S., et al. (2014). Fall-risk-increasing drugs: A systematic review and meta-analysis: III. Others. *Journal of the American Geriatrics Society, 62*(12), 2470–2482. https://doi.org/10.1111/jgs.13142
18. Martinez-Ramirez, D., Giugni, J. C., Almeida, L., Walz, R., Ahmed, B., Chai, F. A., … Okun, M. S. (2016). Association between antidepressants and falls in Parkinson's disease. *Journal of Neurology, 263*(1), 76–82. https://doi.org/10.1007/s00415-015-7947-5
19. Fujiwara, M., et al. (2023). Hypnotics and injuries among older adults with Parkinson's disease: A nested case–control design. *BMC Geriatrics, 23,* 389. https://doi.org/10.1186/s12877-023-03944-9
20. Zhang, Y., & Manning, D. (2021). Persistent polypharmacy and fall injury risk: The Health, Aging and Body Composition Study. *BMC Geriatrics, 21,* 710. https://doi.org/10.1186/s12877-021-02695-9
21. Bhagavathula, A. S., Tesfaye, W., Vidyasagar, K., & Fialova, D. (2022). Polypharmacy and hyperpolypharmacy in older individuals with Parkinson's disease: A systematic review and meta-analysis. *Gerontology, 68*(10), 1081–1090. https://doi.org/10.1159/000521214
22. Sánchez-Vega, D., et al. (2024). Risk factors for falls in Parkinson's disease and other parkinsonisms. *Archives of Gerontology and Geriatrics Plus, 1*(4), 100054. https://doi.org/10.1016/j.aggp.2024.100054
23. Montero-Odasso, M., & Speechley, M. (2018). Falls in cognitively impaired older adults: Implications for risk assessment and prevention. *Journal of the American Geriatrics Society, 66*(2), 367–375. https://doi.org/10.1111/jgs.15267
24. Montero-Odasso, M., et al. (2021). Screening for orthostatic hypotension in Parkinson's disease: Systematic review and meta-analysis. *Journal of Neurology, 268*(8), 3040–3051. https://doi.org/10.1007/s00415-021-10448-w
25. Rudzińska-Bar, M., Bukowczan, S., Stożek, J., Zajdel, K., & Mirek, E. (2013). Causes and consequences of falls in Parkinson disease patients in a prospective study. *Neurologia i Neurochirurgia Polska, 47*(5), 423–430. https://doi.org/10.5114/ninp.2013.38222
26. Kieu, C., et al. (2023). Medications influencing the risk of fall-related injuries in older adults: Case–control and case-crossover design studies. *BMC Geriatrics, 23,* 414. https://doi.org/10.1186/s12877-023-04138-z
27. Albertson, D. J., et al. (2020). Polypharmacy is a risk factor for hospital admission due to a fall: Evidence from the English Longitudinal Study of Ageing. *BMC Public Health, 20,* 1804. https://doi.org/10.1186/s12889-020-09920-x
28. de Vries, M., Seppälä, L. J., Daams, J. G., van de Glind, E. M., Masud, T., O'Mahony, D., & van der Velde, N. (2018). Fall-risk-increasing drugs: A systematic review and meta-analysis. *Journal of the American Geriatrics Society, 66*(4), 783–793. https://doi.org/10.1111/jgs.15326